Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: David Howe who wrote (3471)	7/22/1999 10:31:00 AM
From: Biomaven	Respond to of 10280

From the YC, the Lehman report is now online: lehman.com Confirms Xopenex sales still modest (1200 prescriptions), but management seems confident of a sharp ramp-up in the Fall (to 20,000). (I don't actually know how to interpret this scrip number, given that most sales are to hospitals. Dollar sales in this quarter are also going to be hard to interpret because of stocking issues). Lehman is sticking with $30m sales for 1999. Meridia ICE (s-sibutramine) IND expected in August. Peter